Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives

Since their initial availability in 1997, the thiazolidinediones (TZDs) have become one of the most commonly prescribed classes of medications for type 2 diabetes. In addition to glucose control, the TZDs have a number of pleiotropic effects on myriad traditional and non-traditional risk factors for...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiarelli, Francesco, Marzio, Daniele Di
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2496982/
https://www.ncbi.nlm.nih.gov/pubmed/18561505
_version_ 1782158278479839232
author Chiarelli, Francesco
Marzio, Daniele Di
author_facet Chiarelli, Francesco
Marzio, Daniele Di
author_sort Chiarelli, Francesco
collection PubMed
description Since their initial availability in 1997, the thiazolidinediones (TZDs) have become one of the most commonly prescribed classes of medications for type 2 diabetes. In addition to glucose control, the TZDs have a number of pleiotropic effects on myriad traditional and non-traditional risk factors for diabetes. TZDs may benefit cardiovascular parameters, such as lipids, blood pressure, inflammatory biomarkers, endothelial function and fibrinolytic state. In this review, we summarise the experimental, preclinical and clinical data regarding the effects of the TZDs in conditions for which they are indicated and discuss their potential in the treatment of other conditions.
format Text
id pubmed-2496982
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-24969822008-08-26 Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives Chiarelli, Francesco Marzio, Daniele Di Vasc Health Risk Manag Review Since their initial availability in 1997, the thiazolidinediones (TZDs) have become one of the most commonly prescribed classes of medications for type 2 diabetes. In addition to glucose control, the TZDs have a number of pleiotropic effects on myriad traditional and non-traditional risk factors for diabetes. TZDs may benefit cardiovascular parameters, such as lipids, blood pressure, inflammatory biomarkers, endothelial function and fibrinolytic state. In this review, we summarise the experimental, preclinical and clinical data regarding the effects of the TZDs in conditions for which they are indicated and discuss their potential in the treatment of other conditions. Dove Medical Press 2008-04 2008-04 /pmc/articles/PMC2496982/ /pubmed/18561505 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Chiarelli, Francesco
Marzio, Daniele Di
Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
title Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
title_full Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
title_fullStr Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
title_full_unstemmed Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
title_short Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
title_sort peroxisome proliferator-activated receptor-γ agonists and diabetes: current evidence and future perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2496982/
https://www.ncbi.nlm.nih.gov/pubmed/18561505
work_keys_str_mv AT chiarellifrancesco peroxisomeproliferatoractivatedreceptorgagonistsanddiabetescurrentevidenceandfutureperspectives
AT marziodanieledi peroxisomeproliferatoractivatedreceptorgagonistsanddiabetescurrentevidenceandfutureperspectives

Ejemplares similares